Mu, C.1.2 variants of SARS-CoV2 not found in India so far: INSAOCG

India has so far not seen Mu and C.1.2, the two new variants of SARS-CoV2, and the Delta variant and its sub-lineages continue to the main Variants of Concern in the country, INSACOG, has said

Photo: Shutterstock
Photo: Shutterstock
Press Trust of India New Delhi
2 min read Last Updated : Sep 15 2021 | 1:39 PM IST

India has so far not seen Mu and C.1.2, the two new variants of SARS-CoV2, and the Delta variant and its sub-lineages continue to the main Variants of Concern in the country, INSACOG, the genome sequencing consortium, has said.

The consortium has called for more strongly implementing existing recommendations on sequencing of positive samples from international travellers.

The World Health Organisation (WHO) has added B.1.621 (including B.1.621.1) to the list of Variants of Interest (VOI) on August 30 and christened it Mu. It has also added C.1.2 as a new VOI.

C.1.2 is a sub-lineage of the C.1 variant described in South Africa but did not spread globally, the INSACOG said.

Neither Mu, nor C.1.2 are seen in India so far. Existing recommendations on sequencing of positive samples from international travellers may be more strongly implemented. Monitoring and evaluation of further data appears to be adequate at this time, the INSACOG said in its bulletin dated September 10.

Delta and Delta sub-lineages continue to be the main VOC in India, it added.

The Delta variant has been driving infections in several countries. In India, it led to a deadly second wave.

The INSACOG said Mu has mutations that indicate potential immune escape properties. There appears to be a reduction in neutralisation capacity of convalescent and vaccine sera, similar to that seen for the Beta variant, but this needs to be confirmed by further studies.

Although the global prevalence of the Mu variant has declined and is currently below 0.1 per cent, the prevalence in Colombia (39 per cent) and Ecuador (13 per cent) has consistently increased, according to the WHO bulletin.

It said the C.1.2 variant seems to have undergone many mutations in a short time, and contains mutations of all the three types that have previously been found to be important for transmissibility and immune escape.

The only clinical data for actual transmissibility is a rise from 0.2 per cent in May to two per cent in July, the INSACOG said.

(Only the headline and picture of this report may have been reworked by the Business Standard staff; the rest of the content is auto-generated from a syndicated feed.)

*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

More From This Section

Topics :CoronavirusCoronavirus TestsCoronavirus Vaccine

First Published: Sep 15 2021 | 1:39 PM IST

Next Story